WIPO's decision was absolute and uncompromising: "Machines cannot be inventors. Patent rights are a reward exclusively for human intellect and will."
This ruling was not a mundane bureaucratic rejection. It plunged the multi-trillion-dollar global pharmaceutical industry (Big Pharma), R&D giants, and tech investors directly into a "public domain" crisis. When a machine invents something, who does it belong to? In this in-depth analysis, we examine patent law's "human monopoly" battle against AI, the economic tremors, and the legal crises.
1. The Core of the Case: Why Are Patents Granted to Humans?
The origins of patent law date back to the Venetian Republic. Its philosophy is simple: Society tells an inventor, "Share your invention with us, and in return, we will grant you a monopoly over this invention for 20 years and the opportunity to become wealthy." In other words, a patent is a "reward and motivation" mechanism invented to stimulate human intellect.
WIPO's Legal Rationale
The core argument of WIPO and supporting national courts (especially US Supreme Court precedents stemming from the DABUS cases) is this: An algorithm has no need for money, fame, or incentives. Therefore, granting a patent monopoly to a machine is detrimental to society. To legally be an "Inventor," having legal personhood and mental "conception" is a prerequisite.
Software companies, on the other hand, argued that the concepts of "Applicant" and "Inventor" must be separated. They stated, "The AI can be the inventor, but the commercial owner (Applicant) of the patent should be the company that coded the AI." However, WIPO decreed that for an invention to be patentable, there must unequivocally be a "human inventor" at the very beginning of the chain.
2. Big Pharma's Nightmare: The "Public Domain" Abyss
The most devastating economic impact of this ruling was not felt in the art or software world, but in the Biotechnology and Pharmaceutical Industry (Big Pharma). As of 2026, next-generation cancer drugs or antibiotics are no longer discovered by chemists shaking test tubes in labs for years; they are discovered by massive AI models, like AlphaFold, which solve protein foldings and simulate millions of molecular combinations in seconds.
WIPO's ruling that "AI inventions cannot be patented" legally means this: If a drug was discovered entirely by artificial intelligence, that drug instantly falls into the "Public Domain."
- The Corporate Dilemma: A pharmaceutical company spends $500 million to discover a brand new molecule using AI. However, because it was found by AI, they cannot patent it. Because they cannot get a patent, rival companies start producing the exact same molecule for free the next day and selling it (as a generic drug).
- The Collapse of R&D Investments: Without a patent monopoly (20 years of protection), no investor will pour billions of dollars into drug discovery. WIPO's philosophical ruling protecting the human has, paradoxically, brought medical innovations vital for humanity to a standstill (due to the inability to attract investment).
3. The Era of "Fake Inventors" and Legal Loopholes
Following this harsh ruling by WIPO, tech and pharmaceutical companies have begun resorting to legal trickery to avoid throwing their billion-dollar investments into the trash. Since AI inventions cannot be patented, companies are engaging in "Human-washing."
Even if an AI designed a molecule from start to finish, the lead engineer in the lab makes a false declaration on the patent application form, claiming, "I invented this; I only used the AI as a simple tool like Excel or a microscope." Patent offices, meanwhile, lack the technological infrastructure to prove whether the invention originated from a human mind or the depths of an algorithm.
Patentability Spectrum and Human Contribution
4. Conclusions: What Should the Law Do?
While WIPO's August 2026 decision may look like a victory for classical human-centric patent law, it is an unsustainable situation in the practical world. Our laws were not written for an innovation speed where machines outpace humans.
Granting "legal personhood" and the title of "inventor" to a machine is undoubtedly dystopian and dangerous. However, leaving commercial inventions generated entirely by machines unprotected and declaring them public domain pushes companies into illegal paths. What we need is a new class of property.
Expert Opinion: Burhan Doğuş Ayparlar
WIPO's 'Machines cannot be inventors' decision is a philosophical cry of victory, but it marks the beginning of an economic disaster scenario. The concept of 'Mental Conception,' the cornerstone of patent law, has melted away in the face of algorithmic creativity. The ruling ostensibly protects the human; however, in practice, it forces pharmaceutical and tech giants to build an army of 'Fake Inventors.' To protect their billion-dollar AI inventions, companies will systematically deceive patent offices by registering the AI's achievements under front human engineers.
The solution is not to humanize the machine, but to update the law. What we need is neither to consider the machine an inventor nor to dry up investments by declaring massive innovations Public Domain. The solution is: To create a brand new category of intellectual property called the 'Sui Generis (Unique) AI Invention.'
Instead of the long and powerful 20-year monopoly right granted to classical human inventions, a narrower 'Commercial Developer Right' lasting only 5 or 7 years should be granted to inventions produced by autonomous AI. This way, the company that discovers a drug via AI gains commercial protection long enough to recoup its investment; but because there is no human labor involved, the invention is not withheld from society for a long period like 20 years. We must preserve the concept of the patent as the reward for human genius, yet we must not deny the commercial reality of algorithmic productivity. Otherwise, the law will turn into a dusty book left outside the laboratory.
